Saturday, May 29, 1999 - Question 5

Which of the following statements concerning fluticasone (Flovent) is correct?

A) Fluticasone is approved for treatment of acute exacerbation of asthma.
 
B) Rare case reports of systemic thrombocytopenia have been reported in patients taking fluticasone.
 
C) Fluticasone is a potent beta-2-receptor agonist.

D) Systemic adverse effects are not expected with fluticasone.

E) Cases of serious eosinophilic conditions have been reported in patients taking fluticasone.
 
 

Discussion